Literature DB >> 2652558

Cyclosporin A and hypertension in pediatric renal transplant recipients.

M R Ogborn1, J F Crocker, P Belitsky, A S MacDonald, H Bitter-Suermann, S C Digout.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2652558

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  6 in total

1.  The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.

Authors:  J F Crocker; K W Renton; T L LeVatte; D H McLellan
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

2.  Analysis of hypertension in children post renal transplantation--a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).

Authors:  H J Baluarte; A B Gruskin; J R Ingelfinger; D Stablein; A Tejani
Journal:  Pediatr Nephrol       Date:  1994-10       Impact factor: 3.714

3.  Risk factors for hypertension 3 years after renal transplantation in children.

Authors:  Samantha S Nagasako; Paulo C Koch Nogueira; Paula G P Machado; José O M Pestana
Journal:  Pediatr Nephrol       Date:  2007-05-30       Impact factor: 3.714

Review 4.  Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients.

Authors:  R Büscher; U Vester; A-M Wingen; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

Review 5.  Antihypertensive treatment for kidney transplant recipients.

Authors:  Nicholas B Cross; Angela C Webster; Philip Masson; Philip J O'Connell; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

6.  Arterial hypertension following renal transplantation in children-a short-term study.

Authors:  Samantha Santiago Nagasako; Paulo Cesar Koch Nogueira; Paula Goulart Pinheiro Machado; José Osmar Medina Pestana
Journal:  Pediatr Nephrol       Date:  2003-10-30       Impact factor: 3.714
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.